Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    systematic_literature_reviews_whitepaper
    Demystifying the SLR: “S” stands for systematic

    A structured approach to evidence-based decision-making.

    biosimilars and oncology
    The future of oncology biosimilars

    Considerations for development through 2040.

    icons connected through network_artificail_intelligence
    Decoding AI in software as a medical device (SaMD)

    Regulatory insights and market strategies.

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    Enhancing clinical trials in obesity by integrating COAs and DHTs

    7 October 2025. Register now.

    whitepaper CNS
    Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases

    22 October 2025. Register now.

  • About ICON
    About ICON
    Company history ICON at a glance Healthcare Intelligence ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Medical analytics presentation preview
    Healthcare Intelligence

    Clinical Research. Evolved.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. Insights
  3. Blog page
  4. Improving responses to medical device vulnerabilities

Improving responses to medical device vulnerabilities

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

How can manufacturers improve responses to medical device cybersecurity vulnerabilities?

Medical devices present a great cybersecurity challenge, given their closeness to confidential patient data, not to mention the patients themselves. To compound the issue, a single medical device can have a lifespan of up to 20 years due to a lack of funding and personnel to update them on a regular basis (1). For this reason, many devices often run on obsolete operating systems or have vulnerabilities that have gone unpatched.

These issues cause complications in confronting the threat already posed by hackers who use ingenious methods to compromise medical devices. One such method is monitoring a network with connected medical devices and studying the error messages they generate during normal operation. By leveraging the sensitive software and hardware information the errors often show, hackers can launch a focused attack on those devices (2).

To protect medical devices against these threats, there is a need for an efficient process, involving all stakeholders, to identify and address security gaps. Steps have been made toward this ideal, starting with the FDA cybersecurity guidance. Since its release in 2016, the number of cybersecurity advisories disclosed has been increasing and is projected to double this year, compared to 2017 — with nearly half of them categorised as critical or high (3).

While it is fortunate that there are improvements being made in how medical device cybersecurity concerns are handled, the healthcare industry still lags behind other sectors in this regard.

Data security metrics chart

The number of medical device advisories is projected to double in 2018 (3).

Security threat analysis visualization

Since the release of the FDA guidance, the amount of critical and medium level disclosures have increased significantly (3).

Identifying where improvements should be made

A recent example of a slow response to a vulnerability is a Fortune 500 medical device company  that came under intense scrutiny for its mishandling of product vulnerabilities. The latest concerned the company’s portable computer system, which is used to program and manage cardiac devices and runs on the outdated Windows XP operating system (4).

Researchers from a cybersecurity firm showed that it was possible to hack the device with a fake software deployment network and gain control of any connected devices. This allowed attackers to, for example, remotely disable an implantable insulin pump or take control of a pacemaker system to deliver malware directly to the computers implanted in a patient’s body (5).

The researchers had first reported the exploit to the manufacturer 570 days before its public announcement (5). While the company initially downplayed the risk, it later acknowledged that its response was lacking and pledged to hasten the evaluation and reporting of risks to authorities. Since then, it has released four advisories and an update to its advisory concerning the computer system (5).

A second example is of a different Fortune 500 company’s terminal server that provides administration capabilities to a variety of bedside medical devices connecting to hospital networks. The server uses a web management interface based on RomPager, an embedded web server product commonly use in Internet of Things devices, which has been known to be vulnerable to an exploit called “Misfortune Cookie” (6).

A healthcare cybersecurity research group discovered Misfortune Cookie in the terminal server and found that the exploit can create an arbitrary write to the memory without authentication, letting attackers login without credentials, gain administrator-level privileges, or crash the system — harming server availability and the network connectivity of linked medical devices.

The FDA’s 2016 cybersecurity guidance aimed to mitigate similar cyber security threats by placing emphasis on collaboration between stakeholders. In the case of the terminal server, the manufacturer’s response to the vulnerability follows the FDA’s guidance, where after being notified by the cybersecurity firm, it worked to validate the vulnerability, notify customers, and provide a workaround and an update to the device’s firmware.

While the response was commendable, Misfortune Cookie was publicly known for at least four years before its discovery in the server, showing that there is still room to improve the rate at which vulnerabilities are found and addressed (6). The full details regarding the impact of this vulnerability can be found in this advisory.

Take action to ensure security of your device

To enhance the safety of medical devices, the FDA plans to take actions to provide a robust regulatory framework. The agency has requested additional authority from the United States Congress to require manufacturers to make their devices patchable and to have hospitals set up programs for security researchers to contact them when a vulnerability is found (1). The FDA also has plans to set up a CyberMed Safety Analysis Board in the 2019 fiscal year to provide oversight for digital risks, which can include investigating suspected incidents of compromise, assessing vulnerabilities and adjudicating disputes (1,7).

At ICON, we recommend the use of a cybersecurity vulnerability assessment tool to alert manufacturers of a device’s risks. Our cybersecurity experts can assist in the development of programs that proactively control risks and stay on top of vulnerabilities as they arise. To learn more, please contact us at www.iconplc.com/devices

References

  1. Janofsky A. FDA Plans Cybersecurity ‘Go-Team’ to Strengthen Medical Devices. Wall Street Journal, April 24, 2018.
  2. Helpnet Security. Hackers are finding creative ways to target connected medical devices. September 28, 2018.
  3. Medcrypt. What Medical Device Vendors Can Learn From Past Cybersecurity Vulnerability Disclosures. August 16, 2018.
  4. Hern A. Hackable implanted medical devices could cause deaths, researchers say. The Guardian, August 9, 2018.
  5. Carlson J. Scrutiny continues as Medtronic acknowledges cybersecurity issues with its medical devices. Star Tribune, August 15, 2018.
  6. Med Tech Innovation. Cyber-security vulnerabilities identified in two major medical devices. August 31, 2018.
  7. McGee M.  The FDA's New Digital Health Cyber Unit: What Would It Do? GovInfo Security, September 27, 2018.
In this section
In this section
  • Digital Disruption
    • Clinical strategies to optimise SaMD for treating mental health
    • Digital Disruption: Surveying the industry's evolving landscape
    • AI and clinical trials
      • Impact of AI on Outcomes Based Contracting
      • Using AI for site ID and selection
      • Applying AI to manage the risks and costs of postmarketing requirements
      • Integrating AI into Clinical Research: How AI is Enhancing Clinical Development
    • Clinical trial data anonymisation and data sharing
    • Clinical Trial Tokenisation
    • Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
    • Digital disruption in biopharma
    • Disruptive Innovation
    • mHealth wearables
      • Bring Your Own Device
      • Cybersecurity
        • Addressing cybersecurity for your medical device
      • Digital Endpoints
      • Transforming Medical Device Development with mHealth
    • Personalising Digital Health
    • Real World Data
      • Harnessing technology to maximise Real World Evidence value
      • Meeting Evidentiary Needs with EHRs
      • Post-Market Surveillance for Medical Devices
    • The triad of trust: Navigating real-world healthcare data integration
    • Decoding AI in software as a medical device (SaMD)
    • Software as a medical device (SaMD)
  • Patient Centricity
    • Agile Clinical Monitoring
    • Capturing the voice of the patient in clinical trials
    • Charting the Managed Access Program Landscape
    • Developing Nurse-Centric Medical Communications
    • Representation and inclusion in clinical trials
      • Diversity and inclusion in clinical trials whitepaper
    • Exploring the patient perspective from different angles
    • Patient safety and pharmacovigilance
      • A guide to safety data migrations
      • Taking safety reporting to the next level with automation
      • Outsourced Pharmacovigilance Affiliate Solution
      • The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
      • Sponsor and CRO pharmacovigilance and safety alliances
      • Understanding the Periodic Benefit-Risk Evaluation Report
    • Patient voice survey
    • Patient Voice Survey - Decentralised and Hybrid Trials
    • Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
    • Using longitudinal qualitative research to capture the patient voice
    • Prioritising patient-centred research for regulatory approval
  • Regulatory Intelligence
    • Accelerating access
    • Navigating the regulatory landscape in the US and Japan:
    • An innovative approach to rare disease clinical development
    • EU Clinical Trials Regulation
      • EMA guideline on computerised systems and electronic data in clinical trials
      • EU CTR Whitepaper
    • Using innovative tools and lean writing processes to accelerate regulatory document writing
    • Current overview of data sharing within clinical trial transparency
    • Global Agency Meetings: A collaborative approach to drug development
    • Keeping the end in mind: key considerations for creating plain language summaries
    • Navigating orphan drug development from early phase to marketing authorisation
    • Procedural and regulatory know-how for China biotechs in the EU
    • RACE for Children Act
    • Early engagement and regulatory considerations for biotech
    • Regulatory Intelligence Newsletter
    • Requirements & strategy considerations within clinical trial transparency
    • Spotlight on regulatory reforms in China
    • Demystifying EU CTR, MDR and IVDR
    • Transfer of marketing authorisation
    • Exploring FDA guidance for modern Data Monitoring Committees
    • Streamlining dossier preparation
  • Therapeutics insights
    • Endocrine and Metabolic Disorders
    • Cardiovascular
      • Mitigating the impact of COVID-19 on cardiovascular trials
    • Cell and Gene Therapies
      • Approaching the CAR T-cell therapy horizon
      • Cell and Gene ebook
      • Long-term follow-up studies of cell and gene therapies
      • Mainstreaming Cell & Gene Therapies
    • Central Nervous System
      • A mind for digital therapeutics
      • Challenges and opportunities in traumatic brain injury clinical trials
      • Challenges and opportunities in Parkinson’s Disease clinical trials
      • Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
      • Key Considerations in Chronic Pain Clinical Trials
      • ICON survey report: CNS therapeutic development
    • Glycomics
    • Infectious Diseases
      • Antimicrobial Resistance
      • Considerations for strengthening vaccine development
      • COVID-19 vaccine trials
      • COVID-19 vaccines: Post-authorisation safety surveillance
      • HIV
      • The value of dynamic transmission models
    • NASH
      • The voice of NASH investigators
    • Obesity
      • Addressing obesity's impact across the disease spectrum
      • Trends and challenges in obesity research and clinical trials
      • Obesity and beyond: embracing multi-indication potential during clinical development
      • Survey report: How today’s obesity developers are navigating a multi-indication landscape
    • Oncology
      • ICON survey report: Innovation in Oncology
      • De-risking clinical development of precision medicines in oncology
      • Advances in imaging biomarkers: Estimating drug efficacy with tumour growth rate modelling
      • The future of oncology biosimilars
    • Paediatrics
      • Paediatric Risk Assessment Map
    • Respiratory
    • Rare and orphan diseases
      • Advanced therapies for rare diseases
      • Cross-border enrollment of rare disease patients
      • Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
      • Diversity, equity and inclusion in rare disease clinical trials
      • Identify and mitigate risks to rare disease clinical programmes
      • Leveraging historical data for use in rare disease trials
      • Natural history studies to improve drug development in rare diseases
      • Patient Centricity in Orphan Drug Development
      • The key to remarkable rare disease registries
      • Therapeutic spotlight: Precision medicine considerations in rare diseases
  • Transforming Trials
    • Accelerating biotech innovation from discovery to commercialisation
    • Demystifying the Systematic Literature Reviews
    • Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
    • Linguistic validation of Clinical Outcomes Assessments
    • Optimising biotech funding
    • Adaptive clinical trials
      • Adaptive Design: The Faster Path to Market
    • Best practices to increase engagement with medical and scientific poster content
    • Decentralised clinical trials
      • Biopharma perspective: the promise of decentralised models and diversity in clinical trials
      • Decentralised and Hybrid clinical trials
      • Practical considerations in transitioning to hybrid or decentralised clinical trials
      • Navigating the regulatory labyrinth of technology in decentralised clinical trials
    • eCOA implementation
    • Blended solutions insights
      • Clinical trials in Japan: An enterprise growth and management strategy
      • How investments in supply of CRAs is better than competing with the demand for CRAs
      • The evolution of FSP: not just for large pharma
      • Embracing a blended operating model
      • Observations in outsourcing: Survey results show a blended future
    • Implications of COVID-19 on statistical design and analyses of clinical studies
    • Improving pharma R&D efficiency
    • Increasing Complexity and Declining ROI in Drug Development
    • Innovation in Clinical Trial Methodologies
    • Partnership insights
      • Exploring partnership culture and its impact on outsourcing and operational strategy
    • Risk Based Quality Management
    • Transforming the R&D Model to Sustain Growth
    • Behind Biotech: Stories of science and resilience
  • Value Based Healthcare
    • Strategies for commercialising oncology treatments for young adults
    • US payers and PROs
    • Accelerated early clinical manufacturing
    • Cardiovascular Medical Devices
    • CMS Part D Price Negotiations: Is your drug on the list?
    • COVID-19 navigating global market access
    • Ensuring scientific rigor in external control arms
    • Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
    • Health technology assessment
    • Perspectives from US payers
    • ICER’s impact on payer decision making
    • Making Sense of the Biosimilars Market
    • Medical communications in early phase product development
    • Navigating the Challenges and Opportunities of Value Based Healthcare
    • Payer Reliance on ICER and Perceptions on Value Based Pricing
    • Payers Perspectives on Digital Therapeutics
    • Precision Medicine
    • RWE Generation Cross Sectional Studies and Medical Chart Review
    • Survey results: How to engage healthcare decision-makers
    • The affordability hurdle for gene therapies
    • The Role of ICER as an HTA Organisation
    • Integrating openness and precision for competitive advantage
  • Blog
  • Videos
  • Webinar Channel

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

Related information:

Blog

Cyber attacks have increased dramatically during the COVID-19 pandemic.

Whitepaper

Cybersecurity checklist

Blog

Not If, but when: five cybersecurity threats you can expect

Blog

Addressing the inevitable: managing medical device cybersecurity risks

Webpage

ICON medical device experience and expertise

Blog

The need for new business models under MDR/IVDR

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2025 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?